Muvalaplin shows promise in lowering Lp(a) levels in clinical trial

A clinical trial testing muvalaplin, a novel oral medication, was able to safely and effectively lower high levels of lipoprotein (a), according to late-breaking science presented today at the American Heart Association’s Scientific Sessions 2024.

Filament Health Corp. To List on Nasdaq Through Business Combination With Jupiter Acquisition Corporation | Psychedelic Invest

Filament Health Corp. (OTCQB: FLHLF / NEO: FH / FSE: 7QS), a clinical‐stage natural psychedelic drug development company, and Jupiter Acquisition Corporation (NASDAQ:JAQC) (“Jupiter“), a special

July 20, 2023

Prednisone Did Not Improve Live Birth Rates for Women With Recurrent IVF Failure

Treatment with prednisone did not improve live birth rates among women with recurrent implantation failure compared with placebo, a randomized trial from China showed. Of

May 3, 2023

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

January 9, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.